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Abstract Allergic responses are dependent on the highly spe-
cific effector functions of IgE antibodies. Conversely, antibod-
ies that block the activity of IgE can mediate tolerance to
allergen. Technologies that harness the unparalleled specific-
ity of antibody responses have revolutionized the way that we
diagnose and treat human disease. This area of research con-
tinues to advance at a rapid pace and has had a significant
impact on our understanding of allergic disease. This review
will present an overview of humoral responses and provide an
up-to-date summary of technologies used in the generation of
human monoclonal antibodies. The impact that monoclonal
antibodies have on allergic disease will be discussed, with a
particular focus on allergen immunotherapy, which remains
the only form of treatment that can modulate the underlying
immune mechanisms and induce long-term clinical tolerance.
Keywords Humanmonoclonal antibodies . Allergen
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Introduction
Allergen immunotherapy (AIT) was introduced over a
century ago with the first clinical trial conducted by
Noon and Freeman in 1911 [1, 2]. The aim of AIT is
the induction of clinical tolerance to a sensitizing aller-
gen and has proven highly effective in the treatment of
rhinitis, asthma, and venom allergy. Conventional AIT
involves the subcutaneous injection of increasing doses
of allergen extract over many years. Treatment carries a
risk of inducing adverse side effects including systemic
anaphylaxis [3]; hence, a major goal of research into AIT
has been to improve both safety and efficacy. To this
end, alternative routes of allergen administration have
or are being successfully adopted (e.g., sublingual, oral,
epicutaneous, intralymphatic). Novel vaccine design has
led to the development of alternative forms of treatment
including peptide immunotherapy, immunotherapy with
recombinant allergens or modified allergen extracts, and
the use of adjuvants that stimulate innate immune recep-
tors. In addition, the combined use of monoclonal anti-
body therapy alongside AIT has proven highly success-
ful. Monoclonal antibodies (mAbs) have revolutionized
the way we diagnose and treat human disease. Of the
mAbs now approved or under review, the overwhelming
majority are licensed for use in cancer or autoimmune
diseases. Until recently, the only mAb in clinical use
for al lergic disease was the ant i - IgE ant ibody
Omalizumab (Xolair), which was approved in the USA
in 2003 and in Europe in 2005 for patients with asthma.
In addition, the anti-IL-5 antibody Mepolizumab has now
been approved for use in severe eosinophilic asthma.
Rapid technological advances in medicine over recent
years provide an opportunity to reassess our understand-
ing of allergic diseases and our approach to AIT. The
aims of this review are to assess how advances in mono-
clonal antibody technology could impact the field of al-
lergy and in particular address some of the challenges of
allergen immunotherapy.
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The Breadth of the Humoral Response
Antibodies are secreted glyco-proteins that recognize and bind
to antigen with exquisite specificity through the highly vari-
able fragment antigen binding (Fab) region (Fig. 1). The var-
ious effector functions of antibodies are elicited via the frag-
ment crystallizable (Fc) region (Fig. 1), through engagement
with Fc receptors and other components of the immune
system.
Human antibodies are encoded within the heavy chain im-
munoglobulin locus on chromosome 14 (VH, D, JH, and CH),
the kappa (κ) light chain immunoglobulin locus on chromo-
some 2 (Vκ, Jκ and Cκ), and the lambda (λ) light chain locus
on chromosome 22 (Vλ, Jλ, and Cλ). Antibodies are
produced by B cells which develop in the bone marrow and
express a membrane version of the antibody in the form of a B
cell receptor or membrane immunoglobulin. Following acti-
vation by antigen in the periphery, specific B cells undergo a
series of processes that involve clonal proliferation, isotype
switching (or class switch recombination), and affinity matu-
ration, whereby somatic hypermutation of variable region
genes leads to changes in the affinity of the BCR. B cells that
bind to antigen with high affinity receive survival signals and
may differentiate into memory B cells or plasma cells, the
latter of which gives rise to secretion of high affinity antibod-
ies. Long-lived, terminally differentiated plasma cells migrate
to the bone marrow where they are thought to produce in
excess of 108 antibody molecules per hour [4]. Human anti-
bodies are grouped into five classes (IgD, IgM, IgA, IgE, and
IgG, Fig. 1) with IgA and IgG further divided into two and
four subclasses (IgA1 and IgA2, IgG1, IgG2, IgG3, and
IgG4), respectively, [5].
IgM is expressed as a monomer on the cell surface during B
cell development. Following maturation, IgM is secreted by
activated B cells as a pentamer or, less commonly as a
hexamer, with the addition of the J-chain (Fig. 1). The
multimeric structure of IgM increases avidity of antigen bind-
ing thus enhancing its functional activities including
opsonization and complement fixation. IgM comprises around
10 % of serum antibodies and is important for primary im-
mune responses [6]. A significant proportion of IgM is of low
affinity and often polyreactive; this latter property may be
important for broad recognition of pathogens during primary
responses. IgD is co-expressedwith IgM on naïve B cells prior
to isotype switching. Although IgD+ B cells can differentiate
into plasma cells, this monomeric antibody comprises less
than 0.5 % of serum. The immune function of secreted IgD
is poorly defined; however, class-switched IgM−IgD+ B cells
resident in human respiratory mucosa are thought to play an
important role in immunity to pathogens through direct inter-
actions with basophils [7, 8]. IgG1 is the most well-studied
and hence well-defined of the antibody subclasses owing to its
abundance in serum, comprising around half of all serum an-
tibodies. Like all IgG antibodies [9•], IgG1 is monomeric and
is usually generated during secondary immune responses to
protein antigens, mediating robust effector functions. IgG1
binds with high affinity to IgG receptors and efficiently trig-
gers the complement cascade. IgG2, around 16 % of serum
antibodies, dominates the antibody response to carbohydrates
such that nearly all antibodies specific for bacterial polysac-
charides are IgG2 [10]. IgG3 is the most potent IgG subclass
in terms of effector function, due to its exceptional ability to
activate complement and bind to IgG receptors. Like IgG1, it
is generated in response to protein antigens but is present at
much lower concentrations, comprising just 5 % of serum
antibodies. IgG3 has an unusually long hinge consisting of
62 amino acids compared to IgG2, IgG4 (both 12 amino
Fig. 1 Human Immunoglobulins. Schematic representation of the human
immunoglobulin subclasses, monomeric IgG1, IgG2, IgG3, IgG4, IgA1,
IgA2, IgD, IgE, and polymeric (p) IgA and IgM
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acids), and IgG1 (15 amino acids). IgG4 is the least abundant
IgG subclass comprising just 3 % of serum antibodies. It ap-
pears following long-term exposure to antigen and is generally
regarded as an anti-inflammatory antibody, often associated
with immune tolerance [11]. In addition, IgG4 is unable to
fix complement and binds with lower affinity to IgG receptors
than IgG1 [12•]. Conversely, the spectrum of conditions
known as IgG4-related disease is characterized by high con-
centrations of serum IgG4 and inflammatory infiltration of
IgG4+ plasma cells into tissue [13]. IgA1 and IgA2 are pro-
duced predominantly at mucosal surfaces where they are se-
creted in a dimeric form in combination with a J-chain and an
additional polypeptide, the secretory component (Fig. 1) that
protects the antibodies from proteolytic degradation. In serum,
IgA exists as a monomer with IgA1 accounting for around
13 % of serum antibodies and IgA2 3 %. IgA2 is the predom-
inant subclass in secretions and gut-associated lymphoid tis-
sue whereas IgA1 is produced at higher proportions in sec-
ondary lymphoid tissue [14]. Secretory IgA1 and IgA2 are
poor at activating inflammatory immune responses and are
unable to fix complement but rather act to neutralize antigens
through the process of immune exclusion. In contrast, serum
IgA1 can initiate effective immune responses following bind-
ing to FcαRI on the surface of granulocytes. IgE is the least
abundant isotype in human serum comprising less than 0.01%
of serum antibody in non-atopic individuals and may be up to
ten times higher in allergic individuals, though still low rela-
tive to other isotypes. This low abundance is attributed to the
potent pro-inflammatory immune responses elicited by IgE
through interaction with its receptors FcεRI and FcεRII
(CD23) expressed on the surface of granulocytes and
antigen-presenting cells. IgE is well-known for its central role
in allergic disease [15].
Since their first description by Paul Ehrlich over a century
ago, our understanding of human antibodies has revealed the
incredible diversity that these molecules possess. Human an-
tibodies have broad effector functions that can act at every site
of the human body, often with precise specificity for antigen
targeting. As the basis of humoral immunity, antibodies pro-
vide protection against infectious disease, regulate immune
responses, and maintain immune homeostasis. It is perhaps
no surprise that we have realized the potential of antibodies
for the benefits of human health.
The Advent of Therapeutic Monoclonal Antibodies
for Human Disease
In 1984, Georges Köhler and CesarMilstein were awarded the
Nobel Prize for Medicine for their development of hybridoma
technology nearly a decade previously [16]. This pioneering
technique provided the tools for the generation of monoclonal
antibodies, mAbs (i.e., antibodies of a single specificity) and
ultimately for their diverse application in scientific research
and in diagnostic and therapeutic medicine. Hybridoma tech-
nology involves the fusion of B cells from immunized mice
with myeloma cells to produce an immortalized cell line ca-
pable of continuous production of mAbs specific for a desired
target. Early clinical studies with hybridoma-derived mAbs
found that therapeutic administration resulted in the develop-
ment of immune responses directed towards the murine pro-
teins. These responses caused either a failure of therapy due to
the blocking or neutralizing effects of the anti-mAb, anti-
idiotypic response [17] or immediate or delayed hypersensi-
tivity reactions. Efforts to overcome these adverse effects were
developed during the 1980s following the advent of recombi-
nant technology. One such approach involved the production
of chimeric antibodies in which the murine constant regions
were replaced with human constant regions using molecular
cloning [18, 19]. An added advantage of the incorporation of a
human Fc was their ability to interact with human Fc receptors
and complement components thereby facilitating cooperation
with the immune system. Although this represented a signif-
icant improvement in terms of treatment efficacy, chimeric
antibodies also elicit anti-idiotypic responses. Subsequently,
humanized antibodies were developed in which the hypervar-
iable loops (CDR) from murine antibodies were grafted onto
human framework (FR) regions [20] resulting in a marked
reduction in immunogenicity. The first mAb licensed for use
in humans was muromonab, a murine IgG2a antibody gener-
ated by hybridoma technology, which targets human CD3 to
treat severe steroid-resistant transplant rejection [21].
Although effective, muromonab caused significant adverse
effects due to (i) stimulation of potent T cell responses, (ii)
the production of anti-mouse antibodies, reducing the efficacy
of the treatment, and (iii) isolated cases of anaphylaxis. These
ultimately led to its withdrawal from the market. Since then,
45 mAbs have been approved for use in humans in the USA.
A further four are currently under review and many more in
clinical trials. The overwhelming majority of these are chime-
ric or humanized forms. Despite the success yielded by hu-
manization of mAbs, this technically challenging approach
often resulted in reduced affinity binding of the antibody to
its target, the development of fully human antibodies was
therefore considered an attractive alternative approach.
The Development of Human Monoclonal Antibodies
In 1985, following the development of transgenic mice, Alt
and colleagues suggested that such technology could eventu-
ally be used to Bengineer a mouse to make specific human
antibodies,^ they wrote that Balthough conceptually outland-
ish, such genetic programming experiments may actually be
realized in the not too distant future.^ [22] Their predictions
were correct and less than a decade later the first publications
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described the generation of fully human mAbs from transgen-
ic mice [23, 24]. This approach involves replacing the entire
antibody repertoire of the mouse with genes encoding human
antibodies. Following immunization, standard hybridoma
techniques can be employed to generate fully human mono-
clonal antibodies. Like traditional hybridomas, this technique
is limited to immunogenic, non-toxic antigens but takes
advantage of the in vivo affinity maturation process, resulting
in highly specific antibodies.
Alongside the development of transgenic technology,
phage display provided a novel complementary approach for
the development of human monoclonal antibodies. Phage dis-
play was first described in 1985 [25] and later used to generate
libraries encoding antibody genes [26]. Antibody repertoires
from humans or immunized animals are generated by PCR
amplification of the variable regions of heavy and light chain
fragments. The PCR products are then cloned into a phage
display vector, and DNA encoding a single antibody fragment
is ligated into the pIII (minor) or PVIII (major) coat protein gene
of a single filamentous bacteriophage (such as M13). The
phage is then transduced in E. coli, allowing expression of
the antibody fragment as a fusion protein attached to the cap-
sid. In this way, up to 108 different antibody fragments may be
displayed in a phage Blibrary.^ Antigen-specific antibody frag-
ments are identified through the process of panning whereby
target antigens are immobilized, allowing binding and enrich-
ment of specific antibody fragments [27]. Importantly, the
sequence of the variable regions can be determined thus pro-
viding a link between antibody genotype (i.e., sequence) and
phenotype (i.e., specificity or affinity).
Human B Cells as a Source of Monoclonal
Antibodies
Immortalization with Epstein-Barr virus was one of the first
techniques to allow the generation of monoclonal antibodies
directly from human B cells [28]. Although this method
proved useful in a research setting, the low efficiency of trans-
formation limited its use for antibody discovery. An improved
method for EBV transformation was developed in the labora-
tory of Antonio Lanzavecchia, in which the addition of TLR9
agonists (such as CpG) led to more efficient transformation of
memory B cells [29].
Alternative approaches have since been developed to iso-
late memory B cells from peripheral blood and then isolate
and clone the antibody variable regions using single-cell ex-
pression cloning [30]. By using labeled antigens, specific
memory B cells can be directly isolated by flow cytometry
to generate human monoclonal antibodies with desired spec-
ificities [31]. This method of single B cell cloning has resulted
in the identification of numerous monoclonal antibodies spe-
cific for diverse targets including viruses [32, 33], parasites
[34], and allergens [35••, 36]. Adaptations to this method in-
clude high-throughput culture of single B cells isolated from
blood [37], which allows pre-screening of secreted antibodies
in culture supernatant, so that only cells with desired specific-
ities are subject to cloning and recombinant expression.
The development of high-throughput sequencing technol-
ogy provided a novel approach to mine antibody repertoires
with unprecedented depth [38]. This involves amplification of
the antibody variable region genes followed by high-
throughput sequencing. Typically, peripheral blood is used
as a source of B cells for sequencing but has also been applied
to determine immunoglobulin repertoires in mucosal tissues
[39]. Immunoglobulin repertoire analysis is useful for analyz-
ing the ancestral relationships between related clones and for
examining the diversity and selection of antibodies. Although
this approach has potential for identifying dominant clones of
a given isotype, the ability to sequence only the heavy or light
chains independently meant that information on the natural
pairing of the respective chains is lost. Recent approaches
have been developed to overcome this limitation. Reddy et.al
[40] took advantage of the expansion of bone marrow plasma
cells following immunization or infection to identify and ex-
press the most abundant VH and VL genes within the immu-
noglobulin repertoire. This resulted in a higher efficiency of
antigen-specific antibodies than could be obtained through
random pairing. The use of PCR to physically link IgH and
IgL sequences from individual cells provides another method
of retaining the natural pairing of heavy and light chains
[41••]. In this approach, messenger RNA (mRNA) molecules
are captured in an emulsion inside which the entire VH and VL
regions are amplified by PCR then pooled for sequencing. A
similar approach using Bcell-barcoding^ has also been
employed for paired VH:VL repertoire analysis; here, unique
molecular barcodes are incorporated by Btemplate-switching^
during reverse transcription of mRNA from single B cells.
This novel method was used to clone and express monoclonal
auto-antibodies from the peripheral blood of patients with
rheumatoid arthritis [42••] and Staphylococcus aureus anti-
bodies isolated from patients with S. aureus bacteremia [43•].
Novel Approaches to Allergen Immunotherapy
For over a century, allergen immunotherapy (AIT) has
remained the only form of treatment that can modulate the
underlying mechanisms of allergic disease. Currently, AIT is
used to treat allergic rhinitis, allergic conjunctivitis, allergic
asthma, and insect venom allergy. Both subcutaneous
(SCIT) and sublingual (SLIT) forms of treatment are ap-
proved, though alternative routes (e.g., intralymphatic [44]
and epicutaneous [45]) are under evaluation. In particular,
over the last decade, the potential benefit of oral immunother-
apy (OIT) for the treatment of food allergy has been assessed
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in a large number of clinical trials [46]. Although the efficacy
of AIT is well-documented, it is regarded as an Bunderused^
form of treatment for allergic diseases [47] in part due to the
lack of standardized treatment regimens which results in var-
iations in allergen preparations and differences in clinical
practices from region to region. Several other novel ap-
proaches to improve the efficacy and safety of AIT have been
evaluated, such as the use of recombinant allergens, including
engineered modified Bhypoallergens,^ the use of novel adju-
vants to target allergenic proteins more precisely to immune
modulatory pathways or co-treatment with other anti-allergic
drugs [48].
The use of conventional SCIT alongside anti-IgE treatment
has been assessed in a number of clinical trials. Omalizumab
is a humanized monoclonal antibody directed against the Cε3
domain of the constant (Fc) region of IgE (trade name Xolair,
Novartis) [49]. It is administered intra-venously or subcutane-
ously and binds specifically to human IgE preventing interac-
tions with the high-affinity receptor FcεRI. Due to steric hin-
drance, omalizumab cannot bind to receptor-bound IgE and
thus does not induce cross-linking of effector cells.
Omalizumab has proven efficacy in moderate and severe al-
lergic asthma, and in seasonal and perennial allergic rhinitis
[50]. A single dose results in a decrease of serum IgE and
consequently a downregulation of FcεRI expression on mast
cells and basophils [51]. The use of anti-IgE treatment along-
side AIT was proposed on the basis that it would reduce the
significant risk of systemic anaphylaxis that is associated with
AIT. Indeed, pre-treatment with anti-IgE has been shown to
significantly reduce the incidence of adverse reactions, partic-
ularly during the updosing phase of treatment and results in a
greater reduction in symptoms than AITalone [52–56]. While
large clinical trials of anti-IgE and AIT have thus far been
restricted to studies of allergic asthma and allergic rhinitis,
recent smaller studies combining anti-IgE with OIT provide
promise for this approach in the treatment of IgE-mediated
food allergies [57, 58••]. Omalizumab is unsuitable for a sig-
nificant proportion of patients who have high levels of serum
IgE. Recently, however, a novel human anti-IgE mAb was
generated that may be suitable for such patients. MEDI4212
was produced by phage display and affinity matured using
combinatorial mutagenesis of the CDR regions, generating
an antibody with 100-fold increased affinity for IgE compared
to omalizumab [59•].
The combination of monoclonal antibody therapy with
AIT has been explored with other targets of the allergic re-
sponse. IL-4 is a prototypic T helper 2 (Th2) cytokine pro-
duced primarily by CD4+ T cells as well as by basophils. The
importance of IL-4 in Th2-mediated inflammation and the
induction of IgE class switching prompted the generation of
monoclonal antibodies designed to neutralize IL-4. Like other
mAbs-targeting single cytokines (e.g., anti-IL-5 and anti-IL-
13), the results of clinical trials were disappointing, with
variable levels of efficacy as a standalone treatment [60].
More recently, the use of anti-IL-4 in combination with AIT
for allergic rhinitis was assessed in a double-blind study of 37
patients with seasonal allergic rhinitis [61]. Despite an appar-
ent reduction in the numbers of IL-4-producing cells in pe-
ripheral blood, the concomitant use of anti-IL-4 with AIT had
no additional beneficial effects on the clinical response. The
lack of efficacy of anti-IL-4, in contrast to the synergistic
effects of anti-IgE in combination with AIT, may reflect the
important role of the humoral response in both allergy and
tolerance induction. The induction of blocking antibodies,
particularly of the IgG4 subclass is an important mechanism
in the efficacy of AIT. In fact, blocking antibody responses
have proven therapeutic properties in patients with severe al-
lergic disease.
The Induction of Blocking Antibodies by AIT
In 1937, Robert Cooke and Mary Loveless demonstrated that
co-administration of serum from subjects who had received
multiple subcutaneous injections of ragweed pollen over 3–
12 months, could inhibit immediate allergic responses in the
skin, elicited by intradermal injection of ragweed with allergic
serum [62]. These early experiments demonstrated that
Bblocking antibodies^ are able to inhibit the activity of IgE
in an allergen-specific manner. In 1978, Maurice Lessof and
colleagues took this concept a step further when they demon-
strated that an infusion of gamma-globulin from Bhyperim-
mune^ beekeepers, with high levels of anti-phospholipase
IgG protected against systemic anaphylaxis. Administration
of Bprotective serum^ to five subjects with bee venom allergy
lowered the threshold dose required to induce systemic reac-
tions by 1.5 to 5 times the amount that was previously re-
quired. [63].
Later, similar studies [64, 65] provide proof of concept that
administration of allergen-specific blocking antibodies may
represent a valid therapeutic approach for allergic disease,
one that is more recently gaining favor following the advent
of monoclonal antibody technology [66]. An important con-
sideration for this approach is the polyclonal nature of IgE
responses, which involve multiple epitopes often on several
different allergenic proteins. Thus, a monoclonal antibody di-
rected against a single allergenic epitope would be unlikely to
provide a similar level of passive protection that can be
achieved with hyperimmune serum. The use of multiple com-
binations of monoclonal antibodies is being evaluated for sev-
eral human diseases [67]. In a murine model of allergic asth-
ma, administration of a Bpolyclonal^ mixture of seven recombi-
nant ovalbumin (OVA)-specific IgG2b antibodies to OVA-
sensitized mice provided a better level of protection against
OVA-induced airway inflammation and hyper-reactivity than
a single monoclonal antibody [68].
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Role for Allergen-Specific Antibodies in Vaccine
Design
The availability of well-characterized allergen-specific anti-
bodies could have broad applications for our understanding
and treatment of allergic diseases, from direct therapeutic ap-
plication as passive immunotherapy to the standardization of
allergen extracts for AIT. In addition, allergen-specific mono-
clonal antibodies can facilitate the design of novel forms of
allergen immunotherapy. Inhibiting the activity of IgE has
clear benefits in terms of improving the safety and efficacy
of AIT, exemplified by the concomitant use of anti-IgE. It
follows that hypoallergens (i.e., allergens which lack IgE epi-
topes) would make excellent candidates for allergen immuno-
therapy. Early attempts to alter the allergenicity of immuno-
therapy vaccines through chemical modification (allergoids)
had limited success due to lack of immunogenicity or residual
IgE activity, but re-evaluation of this approach has led to a
number of recent initiatives, most notably the EU-funded
FAST project [69••, 70].
Understanding the molecular determinants of IgE recogni-
tion would allow the rational design of recombinant
hypoallergens for AIT. Epitopes formed by discreet continu-
ous regions of polypeptide (Blinear^ epitopes) can be deduced
by epitope arrays [71]. However, themajority of epitopes from
both inhaled and food allergens are discontinuous or Bconfor-
mational,^ formed by close association of amino acids in the
three-dimensional structure. Such epitopes can only be de-
fined by biophysical approaches such as X-ray crystallogra-
phy or nuclear magnetic resonance (NMR). Of the known 827
allergens in the official WHO/IUIS database (www.allergen.
org), protein database (PDB) structures are available for 92
(11 %) of these [72]. In turn, the structures of 11 allergen-
antibody complexes for six allergens (birch pollen, bee ven-
om, cockroach, cow’s milk, house dust mite, and grass pollen)
have been solved [73–79] (Table 1). All of these complexes
are formed of discontinuous epitopes, except for hyaluroni-
dase from bee venom (Apim 2) which comprises a continuous
stretch of nine amino acids. However, the protruding loop
structure formed by this region in the three-dimensional struc-
ture means that isolated peptides with an identical amino acid
sequence are not recognized by the corresponding antibody or
even by serum IgE [76]. Proof of principle for structure-based
vaccine design is highlighted by studies on Bet v 1, the major
allergen from birch pollen. Based on X-ray crystallographic
analysis of the murine Bet v 1-specific mAb BV16 in complex
with Bet v 1, Spangfort et.al. demonstrated that a single point
mutation in the epitope of Bet v 1, abolishes binding of BV16
and reduces binding of serum IgE by 50 % [80]. Thus, point
mutations in IgE epitopes, guided by analysis of antibody
allergen complex structures, can direct the design of hypoal-
lergenic proteins for therapy of IgE-mediated allergy.
While the advent of component resolved diagnostics has
revolutionized our understanding of patterns of sensitization,
it has also highlighted the surprising disconnect between sen-
sitization and reactivity and the considerable variation in IgE
responses between individuals. The availability of allergen-
specific antibodies directed against clinically relevant, aller-
genic epitopes would allow us to better understand the molec-
ular determinants of allergenicity. Identification of dominant
conformational epitopes through structural studies of antibody
allergen complexes will ultimately lead to the engineering of
recombinant hypoallergens for AIT.
Conclusions
The list of antibodies approved or in clinical trials is constantly
evolving as this form of treatment is adopted in broad areas of
medicine. With rapid improvements in antibody engineering,
antibody expression, and greater understanding of antibody
effector functions, we have entered an era of rapid progress.
Antibodies can now be made smaller (e.g., diabodies [81]),
more stable (e.g., through hinge engineering [82]), more spe-
cific (e.g., in vitro affinity maturation [83]) and ultimately
more efficacious. Our understanding of antibody responses
in disease has improved as a direct result of high-throughput
methods for isolation and characterization of human antibod-
ies and computational approaches to understand how antibody
repertoires are shaped. Given the central role of antibody re-
sponses in allergic disease, we may now take advantage of
these advances to improve our understanding of antibody
Table 1 Allergen-antibody
complex structures Allergen Source mAb clone Species Isotype Technology
Gal d 4 Hen’s egg HyHEL-10 Mouse IgG1 Hybridoma
Bet v 1 Birch pollen BV16 Mouse IgG1 Hybridoma
Bos d 5 Cow’s milk D1 Human IgE Phage display
Api m 2 Bee venom 21E11 Mouse IgG1 Hybridoma
Bla g 2 Cockroach 7C11 Mouse IgG1 Hybridoma
Phl p 2 Grass pollen HuMab2 Human IgE Phage display
Der f 1/Der p 1 House dust mite 4C1 Mouse IgG1 Hybridoma
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allergen interactions and identify disease-relevant epitopes of
clinically relevant allergens. The success of anti-IgE will
hopefully encourage further work into the potential role of
monoclonal antibodies for allergic disease. This form of treat-
ment has the potential to speed up the progressively advancing
progress that has thus far been made in improving the safety
and efficacy of AIT.
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